Department of Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Biol Pharm Bull. 2011;34(9):1469-73. doi: 10.1248/bpb.34.1469.
Probiotics are additives containing live microbes that beneficially affect a host by improving the properties of the host intestinal microflora. Recently, advances in medical treatments have led to increased numbers of immunocompromised patients; some patients contract opportunistic infections of Enterococcus species, which are considered non-pathogenic bacteria. To evaluate the safety of probiotics containing Enterococcus strains, we isolated Enterococcus from six probiotic products and compared the pathogenic genes and antimicrobial susceptibility of the probiotic strains to those of clinical isolates. Our study showed that all Enterococcus strains contained in probiotic products were E. faecium, and no vancomycin-resistant strains were found. In addition, no pathogenic genes, such as ace, agg, gelE, cylM, cylB, cylA, cpd, cob, ccf, efaA(fs), efaA(fm), esp(fs), or esp(fm), were found in the probiotic strains. Pulsed-field gel electrophoresis (PFGE) analysis showed obvious genetic differences between the probiotic strains and the clinical isolates. The data suggested that the probiotic Enterococcus strains were not transmitted to hospitalized patients. Therefore, our results strongly suggest that probiotic products are unlikely agents for causing opportunistic infections.
益生菌是含有活菌的添加剂,通过改善宿主肠道微生物群的特性对宿主有益。最近,医疗治疗的进步导致免疫功能低下的患者数量增加;一些患者感染了肠球菌属的机会性感染,这些细菌被认为是无致病性的。为了评估含有肠球菌株的益生菌的安全性,我们从六种益生菌产品中分离出肠球菌,并比较了益生菌株的致病基因和抗菌药物敏感性与临床分离株的致病基因和抗菌药物敏感性。我们的研究表明,益生菌产品中含有的所有肠球菌均为屎肠球菌,未发现耐万古霉素的菌株。此外,益生菌株中未发现 ace、agg、gelE、cylM、cylB、cylA、cpd、cob、ccf、efaA(fs)、efaA(fm)、esp(fs) 或 esp(fm) 等致病基因。脉冲场凝胶电泳 (PFGE) 分析显示益生菌株和临床分离株之间存在明显的遗传差异。数据表明益生菌肠球菌株不会传播给住院患者。因此,我们的结果强烈表明益生菌产品不太可能是引起机会性感染的原因。